Phio Pharmaceuticals Corp. reported 2025 year-end financial results with net loss of $8.7 million and cash of $21.0 million at December 31, 2025, up from $5.4 million prior year, after $23.7 million in net proceeds from financings extending cash runway into first half of 2027. Phase 1b trial for PH-762 completed dose escalation with favorable safety data; FDA submission targeted for Q2 2026.
Key takeaways
Cash and cash equivalents $21.0 million at December 31, 2025 vs $5.4 million at December 31, 2024
Net loss $8.7 million or ($1.45) per share for year ended December 31, 2025 vs $7.2 million or ($9.08) per share in 2024
Research and development expenses $4.6 million for 2025, up 27% from $3.6 million in 2024
General and administrative expenses $4.6 million for 2025, up 23% from $3.7 million in 2024
Phase 1b PH-762 trial fully enrolled with 22 patients in November 2025; dose escalation complete with favorable safety, tolerability and pathology data
$23.7 million net proceeds from 2025 equity financings and warrant exercises
FDA submission for PH-762 next steps targeted for Q2 2026